# Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus

Study · id `cardio:ct-nct06013020` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06013020](<https://clinicaltrials.gov/study/NCT06013020>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06013020

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 374 participants.

## Technical summary

Registry record NCT06013020. Randomized; no masking; primary purpose prevention. Start 2024-04-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 374 participants (planned count; ClinicalTrials.gov record NCT06013020, source copy `cardio:ctgov-nct06013020-2024-03-19`, retrieved 2026-10-26)
- Planned start: 2024-04-01 (anticipated) (ClinicalTrials.gov record NCT06013020, source copy `cardio:ctgov-nct06013020-2024-03-19`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06013020, source copy `cardio:ctgov-nct06013020-2024-03-19`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06013020, source copy `cardio:ctgov-nct06013020-2024-03-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06013020, source copy `cardio:ctgov-nct06013020-2024-03-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06013020-2024-03-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
- Condition: STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug): NOAC+DAPT
- Intervention (Drug): DAPT
- Lead sponsor: Zunyi Medical College
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Zunyi Medical College (`cardio:org-zunyi-medical-college`)

## Provenance

Content hash: cd1ba42f10a84c5664ddd1285f0cb270baea29edb5f8cfda64ad7fe4935b7933
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
